9/6/2019
ActoBio Announces Phase 1b/2a Trial for ActoBiotics® AG017
ActoBio announces FDA has given permission to an Investigational New Drug (IND) application for Actobiotics® AG017, a therapeutic candidate for celiac disease.
Continue ReadingActoBio announces FDA has given permission to an Investigational New Drug (IND) application for Actobiotics® AG017, a therapeutic candidate for celiac disease.
Continue ReadingCeliac Disease Foundation CEO Joins a Study Developing a Breakthrough Screening Tool The Celiac Disease Foundation asks patient families to participate in research every single day. Why? Because joining research studies and clinical trials is the only way to help scientists better understand this autoimmune disease and ultimately find a...